Daratumumab combined with chemotherapy bridging to allogeneic hematopoietic stem cell transplantation followed by daratumumab and lenalidomide maintenance therapy for primary plasma cell leukemia: report of one case and review of literature
10.3760/cma.j.cn115356-20201008-00240
- VernacularTitle:达雷妥尤单抗联合化疗桥接异基因造血干细胞移植后达雷妥尤单抗联合来那度胺维持治疗原发性浆细胞白血病一例并文献复习
- Author:
Zefeng YANG
1
;
Keqian SHI
;
Renbin ZHAO
;
Peng HU
;
Xin GUAN
;
Chaoran ZHANG
;
Zengzheng LI
;
Liqun YU
Author Information
1. 云南省第一人民医院血液内科，昆明 650100
- Keywords:
Leukemia, plasma cells;
Hematopoietic stem cell transplantation;
Daratumumab
- From:
Journal of Leukemia & Lymphoma
2021;30(8):483-486
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the therapeutic efficacy and prognosis of daratumumab combined with chemotherapy bridging to allogeneic hematopoietic stem cell transplantation (allo-HSCT) followed by daratumumab and lenalidomide maintenance treatment for primary plasma cell leukemia (PCL).Methods:The clinical data of a patient with primary PCL admitted to the First People's Hospital of Yunnan Province in January 2020 were retrospectively analyzed, and relevant literatures were reviewed.Results:The patient was diagnosed with primary PCL and treated with daratumumab combined with BD (bortezomib + dexamethasone) for 1 course and BCDD (bortezomib + cyclophosphamide + liposomaldoxorubicin + dexamethasone) for two courses. The patient was treated with daratumumab combined with allo-HSCT after complete remission. The donor cells were successfully implanted and the chimerism rate of donor cells was 94.36% without acute graft-versus-host disease reaction. And then the patient received intermittent maintenance therapy of daratumumab combined with low dose lenalidomide after transplantation, and the current remission period after transplantation reached 4 months.Conclusions:Daratumumab combined with chemotherapy bridging to allo-HSCT followed by daratumumab and lenalidomide may improve the prognosis of primary PCL and prolong survival time.
